|
Synonyms: 2C4 | Omnitarg® (obsolete trade name) | Perjeta®
pertuzumab is an approved drug (FDA (2012), EMA (2013))
Compound class:
Antibody
Comment: Annotated peptide sequences for this antibody are available in its IMGT/mAB-DB record.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. (2006)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother, 55 (6): 717-27. [PMID:16151804] |
|
2. Badache A, Hynes NE. (2004)
A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell, 5 (4): 299-301. [PMID:15093533] |
|
3. Ferguson KM. (2004)
Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans, 32 (Pt 5): 742-5. [PMID:15494003] |
|
4. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I, Heinrich G et al.. (2013)
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care (Basel), 8 (1): 49-55. [PMID:24715843] |
|
5. Kao Y-H, Vanderlaan M. (2006)
Her2 antibody composition. Patent number: WO2006033700. Assignee: Genentech Inc.. Priority date: 22/07/2004. Publication date: 30/04/2010. |
